For research use only. Not for therapeutic Use.
SMS1-IN-1, compound SAPA 1j, is a novel and the most potent sphingomyelin synthase 1 (SMS1) inhibitor with an IC50 value of 2.1 μM. SMS1-IN-1 has the potential for the treatment of atherosclerosis[1].
SMS1-IN-1 (2.5, 10 and 50 μM) has a dose-dependent inhibitory effect against SMS1, and is against SMS1 with an IC50 value of 2.1 μM[1].
| Catalog Number | I016868 |
| CAS Number | 1807943-38-9 |
| Synonyms | N-[(4-bromophenyl)methyl]-2-[4-(2-phenylethylsulfamoyl)phenoxy]acetamide |
| Molecular Formula | C23H23BrN2O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C23H23BrN2O4S/c24-20-8-6-19(7-9-20)16-25-23(27)17-30-21-10-12-22(13-11-21)31(28,29)26-15-14-18-4-2-1-3-5-18/h1-13,26H,14-17H2,(H,25,27) |
| InChIKey | CZAFIFBJBFDMTP-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)CCNS(=O)(=O)C2=CC=C(C=C2)OCC(=O)NCC3=CC=C(C=C3)Br |
| Reference | [1]. Li YL, et al. Discovery, synthesis and biological evaluation of 2-(4-(N-phenethylsulfamoyl)phenoxy)acetamides (SAPAs) as novel sphingomyelin synthase 1 inhibitors.Bioorg Med Chem. 2015 Sep 15;23(18):6173-84. |
